Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.

نویسندگان

  • Stephanie K Fabbro
  • Sabrina M Smith
  • Jason A Dubovsky
  • Alejandro A Gru
  • Jeffrey A Jones
چکیده

Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias Ibrutinib is an oral inhibitor of Bruton tyrosine kinase (BTK) withmarked activity in several B-cell malignant neoplasms.1 Commonly reported adverse events include diarrhea, infection, fatigue, arthralgias, pyrexia, hypertension, and neutropenia.2 Grade 1 and 2 rashes have been described but are generally self-limited and not treatment limiting. To our knowledge, panniculitis, an inflammation of the subcutaneous adipose tissue, has not yet been described during ibrutinib therapy.We describe 5 patients who developed panniculitis during ibrutinib treatment for lymphoid leukemias.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLCγ2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibruti...

متن کامل

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

The safety and efficacy of ibrutinib, an oral inhibitor of Bruton tyrosine kinase, were evaluated with chemoimmunotherapy (CIT) in a multicenter phase 1b study. Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclophosphamide, and rituximab (FCR) for up to 6 cycles with daily ibrutinib (420 mg) until progressive disease or ...

متن کامل

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.

Ibrutinib is an oral irreversible inhibitor of the bruton tyrosine kinase (Btk) which has shown promising efficacy and excellent tolerability in patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Ibrutinib inhibits BCR signaling, impairs chemokine-mediated adhesion and migration, and induces moderate levels of apoptosis on CLL cells. It also reduces TCR downstream a...

متن کامل

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia. Ibrutinib, the first-in-class inhibitor of Bruton tyrosine kinase, and idelalisib, the first-in-class inhibitor of ...

متن کامل

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-seven patients were enrolled in various clinical trials of ibrutinib, with or without rituximab, at...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • JAMA oncology

دوره 1 5  شماره 

صفحات  -

تاریخ انتشار 2015